Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acitretin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Acitretin | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Any nondermatologic medication. Patients must have: * HIV infection. * Psoriasis involving at least 10 percent of body surface.
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Acitretin has been studied in HIV-positive patients for the treatment of psoriasis, a skin condition that can be severe in people living with HIV. Roche Holding AG developed it, and its clinical development in this setting reached Phase 3.
Acitretin acts as an agonist at retinoic acid receptors and retinoid X receptors, specifically RARA, RARB, RARG, RXRA, RXRB, and RXRG. By activating these nuclear receptors, it modulates gene expression that regulates cell growth and differentiation.
Acitretin is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the company associated with the drug's clinical development program.
Acitretin reached Phase 3 clinical development for HIV infections, specifically for treating psoriasis in HIV-positive patients. The program's single registered trial has been completed, and no trials are currently active.
Acitretin has been evaluated in one registered clinical trial, NCT00002143, titled Treatment of Psoriasis Using Acitretin in HIV-Positive Patients. The Phase 3 trial enrolled 30 participants in the United States and is now completed.
The Phase 3 trial NCT00002143 was an uncontrolled, open-label study, meaning it was not randomized and not double-blinded. It enrolled 30 participants aged 18 years and older of all sexes, and it was not restricted to a biomarker-selected population.